Barrett’s esophagus in 2016: From pathophysiology to treatment

Table 1 Comparison of endoscopic surveillance recommendations for Barrett’s esophagus in currently available guidelines

Guidelines	NDBE	IND	LGD	HDG
BOB CAT[90]	Not recommended1	≤ 12 mo	6-12 mo	Not recommended
ACPG[57]	< 3 cm 3-5 yr	≤ 6 mo	6 mo	Not recommended
	≥ 3 cm 2-3 yr
BSG[58]	< 3 cm 3-5 yr	≤ 6 mo	6 mo	Not recommended
	≥ 3 cm 2-3 yr
ASGE[100]	3-5 yr	No specific time frame	12 mo2	3 mo3
ACP[101]	3-5 yr	Not recommended	No specific time frame	No specific time frame
AGA[59]	3-5 yr	Not recommended	6-12 mo	3 mo3

¹If undertaken, surveillance should be directed at high-risk groups (i.e., composite risk factors including but not limited to 50 years of age or older, white race, male sex, central obesity, the length of the segment, and the symptom duration, frequency and severity), unless the life expectancy ≤ 5 yr;

²Six months to confirm LGD;

³In the absence of eradication therapy. BOB CAT: Benign Barrett’s and Cancer Taskforce; ACPG: Australian Clinical Practice Guidelines; BSG: British Society for Gastroenterology; ASGE: American Society for Gastrointestinal Endoscopy; ACP: American College of Physicians; AGA: American Gastroenterological Association; NDBE: Non-dysplastic Barrett’s esophagus; IND: Indefinite for dysplasia; LGD: Low-grade dysplasia; HGD: High-grade dysplasia.